Eli Lilly Expands Access to Zepbound with Affordable Single-Dose Vials for Obesity Treatment

Eli Lilly and Company (NYSE: LLY) has launched Zepbound® (tirzepatide) single-dose vials, available through its LillyDirect® self-pay channel, significantly expanding access to obesity treatment. Th...